← Back to Search

Probiotic

Probiotic for Lactose Intolerance

N/A
Recruiting
Led By Dennis Savaiano, PhD
Research Sponsored by Purdue University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18 to 65 years of age inclusive at screening
Ability/desire to provide informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

Study Summary

This trial will test if a beneficial bacteria can help people better digest lactose and reduce their intolerance to it.

Who is the study for?
This trial is for adults aged 18-65 who self-report lactose intolerance or maldigestion, can avoid lactose and certain treatments during the study, and are willing to complete all procedures. Excluded are those with severe gastrointestinal conditions, recent surgeries affecting digestion, high BMI (>35), active ulcers, pregnancy, chemotherapy patients, and those with immune diseases.Check my eligibility
What is being tested?
The trial tests if a Bifidobacterium adolescentis capsule improves lactose digestion in intolerant individuals compared to a placebo. It aims to see if this probiotic can change the gut microbiome to better handle dairy products.See study design
What are the potential side effects?
Potential side effects may include digestive discomfort such as gas or bloating due to changes in the microbiome as it adapts to the bifido bacteria. However, specific side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
I am willing and able to give my consent to participate.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Bifidus feeding will change lactose digestion
Bifidus feeding will change lactose intolerance symptoms
Secondary outcome measures
daily symptoms of lactose intolerance will be minimal following return to normal diet

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental GroupExperimental Treatment1 Intervention
Daily Bifidobacterium adolescentis IVS-1,capsule
Group II: Control GroupPlacebo Group1 Intervention
Daily cellulose capsule

Find a Location

Who is running the clinical trial?

Purdue UniversityLead Sponsor
227 Previous Clinical Trials
72,709 Total Patients Enrolled
3 Trials studying Lactose Intolerance
80 Patients Enrolled for Lactose Intolerance
Dennis Savaiano, PhDPrincipal InvestigatorPurdue University
4 Previous Clinical Trials
928 Total Patients Enrolled
3 Trials studying Lactose Intolerance
80 Patients Enrolled for Lactose Intolerance

Media Library

Bifidobacterium adolescentis IVS-1 capsule (Probiotic) Clinical Trial Eligibility Overview. Trial Name: NCT05668468 — N/A
Lactose Intolerance Research Study Groups: Control Group, Experimental Group
Lactose Intolerance Clinical Trial 2023: Bifidobacterium adolescentis IVS-1 capsule Highlights & Side Effects. Trial Name: NCT05668468 — N/A
Bifidobacterium adolescentis IVS-1 capsule (Probiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05668468 — N/A
~11 spots leftby Jun 2025